Let’s discuss the extensive-stage setting first. Beyond chemotherapy, immunotherapies have also been investigated in small cell lung cancer (SCLC). What are the main differences between these 2 classes of medication, and why was it necessary to study these in SCLC?
Durvalumab has also shown to have positive results as a first-line treatment in extensive-stage lung cancer in the CASPIAN trial. Where does this treatment fit into your treatment algorithm?
- What are the adverse events to monitor for, and how do you manage them?
Can you describe the results of the IMpower133 trial with atezolizumab in extensive-stage SCLC and how these impact your practice?
- In which patients do you use atezolizumab?
